Ironwood Pharmaceuticals

IRWD

Market cap $735M

The pharmaceutical sector is famously volatile, usually driven by the binary outcomes of clinical trials. A drug either works, sending the stock to the moon, or it fails, causing a crash.

Innovation is at its peak in the Zacks Medical-Drugs industry. SLNO, NKTR, RIGL, IRWD and MRKR may prove to be good additions to one's portfolio.

IRWD shares jump on upbeat 2026 revenue guidance amid rising Linzess demand in the United States. The company also provides a key pipeline update.

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced financial guidance for full year 2026. “Throughout 2025, we made significant progress in maximizing LINZESS while delivering sustained profits and cash flows in an effort to strengthen our financial position and maintain compliance with debt covenants over the coming.

Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock?

Ironwood and Puma Biotechnology are advancing therapies for gastrointestinal disorders and cancer, respectively. Rising sales of key drugs fuel 2026 prospects.

Ironwood Pharmaceuticals (IRWD) remains undervalued despite a failed $1bn Vectiv Bio acquisition and subsequent stock plunge, with Linzess providing strong recurring revenue. IRWD's apraglutide Phase 3 trial met primary endpoints but failed to surpass Takeda's Gattex, prompting the FDA to require another confirmatory study before approval. Linzess sales are robust, with Q3 2025 sales up 40% year-on-year and new pediatric approval, but looming 2029 patent expiry poses a long-term risk.

Ironwood gains momentum as rising U.S. demand for Linzess drives strong profit growth during the third quarter.

Ironwood's 110% monthly surge follows upbeat third-quarter results and raised 2025 outlook, powered by increasing Linzess demand.

Ironwood posts a stellar third-quarter beat with higher revenues and raises 2025 outlook on Linzess-driven strength.